XDH and myeloid sarcoma: Recently and for the first time, Honorat and colleagues found, in the EAE mouse model of MS, that the activity of XO was increased in the serum and within the CNS of the mice with experimental inflammatory demyelination, and the administration of febuxostat was able to reduce the clinical signs of the disease, suppress the excess ROS production from infiltrating macrophages and microglia, improve mitochondrial function and prevent neurodegeneration in both relapsing–remitting and secondary progressive EAE [59,60].